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Purpose. The antimicrobial eﬀect of a silver-coated tumor endoprosthesis has been proven in clinical and experimental trials.
However, in the literature there are no reports concerning the eﬀect of elementary silver on osteoblast behaviour. Therefore, the
prosthetic stem was not silver-coated because of concerns regarding a possible inhibition of the osseointegration. The aim of the
present study was to investigate the eﬀect of 5–25mg of elementary silver in comparison to Ti-6Al-4V on human osteosarcoma
cell lines (HOS- 58, SAOS). Methods. Cell viability was determined by measuring the MTT proliferation rate. Cell function was
studied by measuring alkaline phosphatase (AP) activity and osteocalcine production. Results. In the HOS-58 cells, the AP activity
was statistically signiﬁcant (P<0.05) higher at a supplement of 5–10mg of silver than of Ti-6 Al-4V at the same doses. For
both cell lines, a supplement above 10mg of silver resulted in a reduced AP activity in comparision to the Ti-6 Al-4V group, but
a statistically signiﬁcant diﬀerence (P<0.05) was observed at a dose of 25mg for the SAOS cells only. At doses of 20–25mg
in the HOS-58 cells and 10–25mg in the SAOS cells, the reduction of the proliferation rate by silver was statistically signiﬁcant
(P<0.05) compared to the Ti-6 Al-4V supplement. Discussion. In conclusion, elementary silver exhibits no cytotoxicity at low
concentrations. In contrast, it seems to be superior to Ti-6 Al-4V concerning the stimulation of osteogenic maturation at these
concentrations, whereas at higher doses it causes the known cytotoxic properties.
Copyright © 2007 Jendrik Hardes et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The antimicrobial eﬀect of silver-coated medical devices has
been reported in previous studies [1–3]. Silver is in com-
parison to other metals low cytotoxic [4]. Toxic side eﬀects
have been described for blood concentrations of 300ppb
in form of argyrosis, leukopenia, liver, and kindney dam-
age [1, 3]. However, systemic or localized cytotoxic side ef-
fects have been reported in doses below 300ppb [5]. Inhibi-
tion of the proliferation of keratinocytes and ﬁbroblasts after
treatment with silver-sulfadiazin have been described [6, 7].
There are some reports describing a chronic inﬂammatory
reactioninpatientstreatedbyasilver-coatedheartvalve.The
authors assume a toxic reaction deriving from the silver re-
leased from the impregnated sewing cuﬀ, which may lead to
aninhibitionofnormalﬁbroblastresponse[8].Nevertheless,
with the use of silver one has to consider its dose-dependent
cytotoxic side eﬀects [9]. According to this, other authors
have described no cytotoxicity of silver-coated medical de-
vices [3, 10–12].
A silver coating of orthopedic medical devices in humans
has not been described before. In a previous animal trial
the antimicrobial eﬃcacy and the absence of histologically
proven cytotoxic side eﬀects of a silver-coated diaphseal im-
plant in a rabbit have been reported [9]. Nevertheless, the
used prosthetic stem was not silver coated because of con-
cerns regarding a possible inhibition of osteoblasts by silver.
To our knowledge the eﬀect of elementary silver on bone
matrix producing cells has not been investigated until now.
To observe possible dose-dependent eﬀects of silver on os-
teoblasts, the MTT rate of two osteosarcoma cell lines repre-
sentingdiﬀerentstagesofosteogenicmaturationhasbeenin-
vestigated. Further osteoblast function has been determined
by measuring the AP activity and the osteocalcine produc-
tion after addition of 5mg to 25mg silver powder in com-
parision to 5mg to 25mg of Ti-6Al-4V powder.2 Sarcoma
2. MATERIALS AND METHODS
In the current study ﬁve cell culture series and one control
series have been used for the silver group and the Ti-6Al-4V
group, respectively. In the silver group a silver powder sup-
plement has been added in concentrations ranged from 5mg
to 25mg in 5mg steps. In the titianium group a Ti-6Al-4V
powder supplement has been added in the same manner. All
powder supplements have been of the same particle size of
90µµm or less. The incubation period was 48 hours. All trials
have been performed four times in each individual cell cul-
ture series. The reported values represent the mean value of
the four trials.
2.1. Cellcultures
HOS 58 is an established osteosarcoma cell line, originally
isoloated from an osteosarcoma of a 21-year-old man (Insti-
tute of Pathology, University of Giessen) [13]. It is charac-
terized by a comparatively low proliferation rate. SAOS 2 (11
years, female) is in contrast to the previous one character-
ized by a high proliferation rate and is known to be capable
of bone production [14].
Cells have been maintained in ISCOVE medium with a
supplement of 10% of FCS (Gibco), 100IU/ml of penicillin,
100µg/ml of streptomycin in a humidiﬁed atmosphere of
95% air, and 5% CO2 at 37◦C.
In each individual cell culture, cells have been cultivated
at a starting density of 20000 cells/well in six well plates
(Nunc). The cells have been placed on the bottom and have
been incubated for 24 hours. The supplements have been
added and build up a layer onto the cell culture.
2.2. Alkalinephosphatase
The AP activity has been measured with the protein assay of
Lowry (p-nitrophenylphosphate assay, 37 C, 405nm, Triton-
X-100).Thespeciﬁcactivityhasbeencalculatedasu/µmpro-
tein.
2.3. Osteocalcin
The production of osteocalcine has been measured with the
IBL-osteocalcin kit (IBL Hamburg). In this test monoclonal
osteocalcine antibodies have been used. These antibodies
have been detected by the use of HRP conjugated link an-
tibodies (measurement at 405nm).
2.4. Cellproliferationrate
The proliferation rate has been considered with the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide as-
say (MTT). In this test the mitochondrial activity has been
measured by splitting tetrazolium salts with mitochondrial
dehydrogenases in living cells only. The optical density has
been read with a Microplate Reader BIO-RAD Model 550
(Bio-Rad Laboratories) at 540nm, and with the use of a ref-
erence wavelength at 690nm.
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Figure 1: Alkaline phosphatase activity of the SAOS cell line after
supplementation of 5–25mg silver or titanium.
2.5. Statisticalanalysis
The statistical evaluation has been performed with the pro-
gramsExcelandStatisticalPackageforSocialSciences(10.0).
To determine diﬀerences in the silver-, Ti-6Al-4V- and con-
trol group, the Mann-Whitney-U-test has been used.
3. RESULTS
3.1. Alkalinephosphataseactivity
In the control group the AP activity was 254.7u/µm for the
SAOS cell line. The supplement of 5–10mg of silver resulted
inanincreaseoftheAPactivityto422.9u/µm.Theactivityat
these silver doses was higher than with a Ti-6Al-4V supple-
ment, but not statistically diﬀerent. Even with a supplement
of 15mg of silver the activity was above the value of the con-
trol group with 298.8u/µm. With a supplement of 25mg the
activity decreased to 128.2u/µm (see Figure 1). The Ti-6Al-
4V supplement resulted in an comparable activity increase to
418.0u/µma t1 0m g ,b u tw i t ho n l yas l i g h td e c r e a s ei nc o n -
centrations above 10mg. With a supplement of 25mg, the
activity decreased to 278.6u/µm (see Figure 1). This activity
is still above the value of the control group. Statistically sig-
niﬁcant diﬀerences (P<0.5) between the two groups could
be observed with a supplementation of 25mg silver/Ti-6Al-
4V only.
The AP activity in the control group was 172.3u/µmf o r
the HOS-58 cell line. The supplement of 5–10mg of silver
resulted in an increase of the AP activity to 218.6u/µm. The
supplement of 15mg of silver leads to a more pronounced
decrease (100.6u/µm) than in the SAOS cell line. With a
supplement of 25mg the activity decreased to 59.0u/µm
(see Figure 2). The Ti-6Al-4V supplement resulted in an
increased activity (189.2u/µm) at 5mg, whereas with the
supplement of 10 mg the activity (128.7u/µm) was be-
low the value of the control group. The supplement of
more than 10mg resulted in slight activity diﬀerences onlyJendrik Hardes et al. 3
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Figure 2:AlkalinephosphataseactivityoftheHOS-58celllineafter
supplementation of 5–25mg silver or titanium.
(see Figure 2). A silver supplement of 5mg and 10mg re-
sultedinasigniﬁcanthigherAPactivitythanthesupplement
of Ti-6Al-4V at the same doses (P<. 05).
3.2. Osteocalcineactivity
In contrast to the AP activity there were no statictically sig-
niﬁcant diﬀerences between the silver and Ti-6Al-4V supple-
ment. In the control series the mean osteocalcine concen-
tration was 26.5ng/ml for the SAOS cell line. In the series
with the SAOS cell line the osteocalcine concentration in-
creasedfrom26.6ng/ml(5mgofsilver)to27.1ng/ml(25mg
of silver), but never reached the concentration of the control
group. With the Ti-6Al-4V supplement the osteocalcine con-
centration was 27.1ng/ml at 5mg and 25.6ng/ml at 25mg.
In the control series the mean osteocalcine concentra-
tion was 27.3ng/ml for the HOS-58 cell line. The osteocal-
cine concentration was 26.0ng/ml at 5mg silver supplement
andincreasedto28.0ng/mlat25mgsilversupplement.With
the Ti-6Al-4V supplement the concentration was 27.6ng/ml
(5mg) and 26.3ng/ml (25mg), respectively.
3.3. Cellproliferationrate
In the SAOS group, the MTT proliferation rate decreased
from 77.0% (5mg of silver) to 5.4% (15mg) and showed a
slight increase in concentrations of 20mg (9.5%) and 25mg
(8.1%) in comparision to the control group (100%) (see
Figure 3). A decrease of the proliferation rate with increased
Ti-6Al-4V concentrations was measured also. However, the
proliferation rate was throughout higher than in the silver
group with a maximum value of 82.4% (5mg). With a sup-
plement of 25mg the proliferation rate was still 39.2% in
comparision to the control group. As in the silver group the
lowest proliferation rate was measured with a supplement of
15mg (35.1%) and showed an increase to 40.5% (20mg). In
general, the diﬀerences between a silver and Ti-6Al-4V sup-
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Figure 3: MTT rate of the SAOS cell line after supplementation of
5–25mg silver or titanium.
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Figure 4: MTT rate of the HOS-58 cell line after supplementation
of 5–25mg silver or titanium.
plementwerestatisticallysigniﬁcantatconcentrationshigher
than 5mg (P<0.5).
In the silver group the proliferation rate of the HOS-58
cell line decreased continuously from 87.7% (5mg) to 5.3%
(25mg) (see Figure 4). The proliferation rate in the Ti-6Al-
4V group was obviously less reduced than in the silver group
with a MTT rate of 82.5% (5mg) to 52.6% (25mg). Statis-
tically diﬀerences (P<0.5) in the proliferation rate between
the two groups were seen at 20mg and 25mg supplements
only.
4. DISCUSSION
Infection is the most common and serious complication in
the reconstruction of large bone defects in tumor and revi-
sion surgery by megaendoprostheses. In literature infection4 Sarcoma
rates between 8% and 13% have been reported [15–17]. Sec-
ondaryamputationorhipdisarticulationisinsomecasesthe
only solution [18, 19].
Silver coating of medical devices has proven antibacte-
rial activity in vitro and in vivo [1–3, 20]. Elementary sil-
ver exhibits a dose-dependent cytotoxity [9]. According to
this there are few studies reporting diﬀerent results concern-
ing the cytotoxicity of silver. Inhibition of the proliferation
of keratinocytes and ﬁbroblasts after treatment with silver-
sulfadiazin has been described [6, 7]. In contrast, Tweden et
al. [3] have reported no evidence of silver toxicity to cultured
ﬁbroblastsuntilconcentrationsreachedlevelsof1200ppb.In
a previous animal trial we have reported about reduced in-
fection rates of silver-coated diaphyseal implants in compar-
ision of titanium implants in rabbits after artiﬁcial contami-
nation with S. aureus without histologically proven cytotoxic
local or systemic side-eﬀects [9]. The stems of the implants
have not yet been silver coated because of scepsis concerning
the osseointegration. Though, a silver coating of prosthetic
stems would be desirable in order to achieve antibactericidal
silver concentrations in the bone.
Osseointegration is a process in which a stable anchorage
of an implant in the bone is achieved by direct bone to im-
plant contact without any intervening ﬁbrous tissue [21, 22].
Osseointegration is inﬂuenced by various factors such as the
used materials, design and size of the implant, and the sur-
face characteristics of the medical device [21–24]. The ba-
sic prerequisite for osseointegration is the biocompatibility
of the used material. Titanium has got well-known proper-
ties concern prostheses ingrowth in the bone, long term sta-
bility, tissue biocompactibility, and osseointegrative eﬀects
[22, 23]. Therefore titanium and titanium alloys are the most
often used metals in modern cementless endoprosthetics of-
ten combined with a hydroxyapatite coating [22, 24, 25].
In literature there have been no studies describing os-
seointegration of silver-coated materials. Only a few reports
describe the eﬀect of silver on osteoblasts [10, 26]. Bosetti
et al. [10] reported no cytotoxicity of silver-coated stain-
less steel on osteoblast-like cells in vitro determinded by cell
morphology. They further described no decreased AP activ-
ity and no elevation of lactat dehydrogenase indicating a cell
damage. Nevertheless, in this study no diﬀerent silver con-
centrationshavebeenused.Altetal.[10]exposedhumanos-
teoblast cells (hFOB cell line) to bone cement with addition
of nanoparticulate silver. They examined by ﬂuorescence mi-
croscopy that all cells were vital and showed a typical mesh-
like growth pattern after 48 hour incubation period. Kramer
et al. [27] investigated the osteoinductive properties of silver
on demineralized bone matrix implanted in the paraspinous
muscles of rats. In this experiment, they described osteoin-
ductive capacity of silver at low concentrations (10−3 Ma n d
10−4 M) but not at higher concentrations (10−5 M). They
concluded that there must be a concentration of silver which
can instill a maximum antibacterial eﬀect while retaining al-
most 100% of the osteoinductive capacity.
The current study conﬁrms the results of Kramer et al.
[27] concerning the dose-dependent eﬀects of silver on os-
teoblasts in vitro. A silver supplement below 10mg exhibits
an increase of diﬀerentiation markers (AP activity) of os-
teoblastic phenotype indicating a stimulation of osteoblastic
diﬀerentiation superior to a Ti-6Al-4V supplement. For the
HOS-58 cell line the diﬀerences have been statistically signif-
icant (P<0.5). At higher doses (>10mg) silver caused lower
AP activity in comparison to a Ti-6Al-4V supplement indi-
cating lesser biocompatibility. Nevertheless, statistically dif-
ferences could be observed at doses of 25mg for the SAOS
cell line only.
The reduction of the proliferation rate has been more
pronounced with a silver supplement than with a Ti-6Al-
4V supplement. At doses up to 10mg of silver the reduced
proliferation rate (40.4% for HOS-58) should not be seen
as a cytotoxic eﬀect, moreover it is believed to be a step in
osteogenic maturation. This assumption is conﬁrmed by in-
creased AP activity at these doses indicating osteogenic dif-
ferentiation. Nevertheless, at doses above 10mg of silver the
proliferation rate shows a more pronounced reduction com-
bined with decreased markers of osteogenic diﬀerentiation.
Therefore, at these doses silver should be seen as cytotoxic,
particularly because of a proliferation rate below 10% for
both cell lines. In contrast, titanium is known to have a low
cytotoxicity [22]. Yao et al. [28] reported that the addition
of titanium particles in low doses (4.5 × 107 particles per
milliliter) caused no reduced proliferation rate of osteosar-
coma cell lines. In the current study, even with a 25mg Ti-
6Al-4V supplement the proliferation rate is still above 50%
for both cell lines. Statistically signiﬁcant diﬀerences beween
the silver and the titanium group can still be detected in the
SAOS cells at 10–25mg supplements, whereas in the HOS-
58 cells statistically signiﬁcant diﬀerences can be observed at
20–25mgonly.Thecytotoxiceﬀectofsilverseemstobemore
pronounced in high proliferative cell lines, whereas in cells
with a lower proliferation rate (e.g., normal osteoblasts) this
eﬀect is less distinctive. Therefore, it can be assumed, that in
normal osteoblasts the reduction of the proliferation rate at
low silver doses will not inhibit osseointegration.
Osteocalcin as a marker for matrix mineralization did
not show any diﬀerences between the two groups in the mea-
suredtimeperiod.Theosteocalcinewasexpressedatlowlev-
els for all supplement concentrations in both cell lines. As a
marker for the late phase of osteoblastic diﬀerentiation os-
teocalcin is found in mature and fully developed mineralized
bone matrix. Our results seem to be an indicator of begin-
ning bone turnover. Though osteocalcine production in os-
teosarcoma cell lines and especially in SAOS cells is contro-
versial. Ahmad et al. [29]r e p o r t e dl o wa m o u n to fo s t e o c a l -
cine mRNA in SAOS-2 cultures treated with 1,25-(OH)2D3
for 10 weeks. Other studies reported simular results of low
osteocalcine production in diﬀerent osteosarcoma cells in in
vitro studies [30].
Our results conﬁrm the fact that silver at low concen-
trations is not cytotoxic for osteoblast in vitro. On the con-
trary, it seems to stimulate osteogenic maturation of undif-
ferentiated osteosarcoma cells. The diﬃculty in using sil-
ver for antibacterial coating of prosthetic stems is the de-
termination of the “therapeutic window” [26] in which sil-
ver acts bactericidal and additionally stimulates osteogenicJendrik Hardes et al. 5
diﬀerentiation. Nevertheless, statements concerning the os-
seointegrative properties of silver-coated stems can not be
made yet, because osseointegration depends on many factors
a ss t a t e da b o v e .W ep e r f o r mn o wa ni nv i v os t u d y ,i nw h i c h
silver-coated versus titanium hip stems will be implanted in
beagles. The osseointegration will be measured by RSA tech-
niqueandimportantly histologicallyafterafollow-upperiod
of twelve months.
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